Questions About Gantenerumab Failure Remain, But Roche Is Not Yet Finished With Alzheimer’s

Full Data Presented At CTAD Congress

 
• By Andrew McConaghie

Roche’s global head of neurodegeneration, Rachelle Doody, talks to Scrip about the failure of gantenerumab and its next-generation ‘brain shuttle’ technology for Alzheimer’s disease.

Roche_Basel
Roche's 'brain shuttle' technology is a promising 'next gen' technology, but for now has missed out while Eisai and Biogen head to market • Source: Image archive

More from Business

More from Scrip